On September 15, 2011 Rx&D (now Innovative Medicines Canada), CIHR and ACAHO (Now HealthCareCAN) launched the National Clinical Trials Summit which has now resulted in an action plan to Help Attract More Clinical Trials to Canada. Today this initiative has resulted in the launch of the Canadian Clinical Trials Coordinating Centre (CCTCC) designed to oversee its implementation.
Linda Barrett-Smith, Director, Research Ethics & Alberta Clinical Research Consortium (ACRC)
Dr. Stanislav Glezer, Vice-President Medical Affairs, sanofi-aventis
Recruitment & Retention
Diane Simmons, President and CEO, Center for Information and Study on Clinical Research Participation
Sandra Gazel, Associate Director, Clinical Operations, Abbott
Dr. Neil Maresky, Vice-President, Scientific Affairs, AstraZeneca Inc.
Karen Arts, Director, Business Development, Clinical Trials, Ontario Institute for Cancer Research & Co-Founder and Chair of Board of Directors Network of Networks (N2)
Linda Bennett, Executive Director, Canadian Rheumatology Research Consortium
Dr. Shurjeel Choudhri, Senior Vice-President and Head, Medical and Scientific Affairs, Bayer Inc.
To Your Health & Prosperity – An Action Plan to Help Attract More Clinical Trials to Canada (March 30, 2012)
This is the action plan from the 2011 National Clinical Trials Summit. It is the third and final paper in a trilogy of papers from the clinical trial summit hosted by Rx&D, CIHR, and ACAHO. It reflects a vision for Canada as a premier country for industry led clinical trials. The goals of the action plan are to help halt and reverse a downward investment trend, improve overall business practices as they pertain to clinical trial start up times, and present a forward looking business opportunity through information and incentives for global companies. The action plan contains nine recommendations in three strategies. The first recommendation encapsulates its implementation through potential alignment with the Strategy for Patient Oriented Research (SPOR). This final version of the action plan also contains an appendix which reflects feedback given on the final draft. This feedback is largely supportive and also instructional as it pertains to the implementation of this plan. AS such, it is considered part of the final document.
Towards an Action Plan – Proceedings from the 2011 Clinical Trials Summit (March 23, 2012)
This is the second in a trilogy of papers from the September 2011 Clinical Trials Summit hosted by Rx&D, CIHR and ACAHO. The goal of the summit is to enable development of an action plan that will help Canada regain capacity to attract clinical trial opportunities. The proceedings reflect a day long discussion with 130 experts from various sectors on how to improve cost, quality, speed and relationships as they pertain to clinical trial start up times and other issues. They include discussion notes from break out rooms on streamlining ethics reviews, patient recruitment, facilitating administrative issues, cost issues, and strategic infrastructure. The proceedings include interpretation of the comments into potential actionables. These actionables were circulated to delegates in November for feedback which now appears in an Appendix. The feedback and proceedings will form the basis of the action plan.
Canadian Clinical Trial Summit – Starting the Conversation (September 15, 2011)
On September 15, 2011, ACAHO, Canada’s Research-Based Pharmaceutical Companies (Rx&D) and the Canadian Institutes of Health Research (CIHR) co-hosted a National Clinical Trial Summit designed to help reinvigorate and re-establish Canada’s tradition of excellence in clinical trials, bringing together over 120 experts from patient care sites, research, academia, government and industry in a first time ever collaboration of this nature. To assist, a background document entitled “Starting the Conversation” offers a very high level summary of what we know about the human, social and economic value of clinical trials, commonly discussed strengths, weaknesses, opportunities and challenges; strategies that other countries are using to attract clinical trial investments, and some key questions for Canada to consider going forward.
Documents developed by the Streamlining of Health Research Ethics Review External Advisory Committee